Monalizumab (Anti-Human CD159a) | CD markers inhibitor | Read Reviews & Product Use Citations

Monalizumab (Anti-Human CD159a) is a novel, first-in-class humanized immunoglobulin G4 monoclonal antibody immune checkpoint inhibitor that targets the inhibitory CD94/NKG2A receptors.

Click to purchase the isotype control of Monalizumab (Anti-Human CD159a)

Purity & Quality Control

Batch: Purity: 99% Protein concentration: 10.7mg/ml Endotoxin Level: ＜1EU/mg

99

Choose Selective CD markers Inhibitors

Biological Activity

Description	Monalizumab (Anti-Human CD159a) is a novel, first-in-class humanized immunoglobulin G4 monoclonal antibody immune checkpoint inhibitor that targets the inhibitory CD94/NKG2A receptors.

References
[1] Hwang M, et,al. J Clin Pharmacol. 2023 Jul;63(7):817-829.

References

[1] Hwang M, et,al. J Clin Pharmacol. 2023 Jul;63(7):817-829.

Product Details

CAS No.	1228763-95-8
Molecular Weight	150 kDa
Isotype	Human IgG4-Kappa
Application	Monalizumab (Anti-Human CD159a)
Purification	Protein G
Sterility	0.2 μM filtered
Formulation	PBS Buffer, PH 7.4
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field